Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial
- Tuesday, July 25, 2023, 7:13
- Business
- Add a comment
NEW YORK, July 25, 2023 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that the first patient has been dosed in its Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal…
About the Author
adminasapcorp has written 39487 stories on this site.